Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Cigall Kadoch
Dana Farber Cancer Inst, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Foghorn Therapeutics, Inc.
Payment for services (e.g., consulting fees, honoraria, paid authorship)
please see attached
Reversing Oncogenic BAF Complex Structure & Function: New Therapeutic Approaches
Recent whole genome sequencing efforts in human cancers have implicated aberrant chromatin remodeling as a significant, wide-spread player in oncogenesis, yet the biochemical mechanisms which result from such genomic changes remain unclear. Harnessing the power of disease settings in which the perturbation to a chromatin remodeling complex is the clear driving event affords a new opportunity for mechanistic discovery and therapeutic development. This proposal aims to uncover a new class of small molecule probes which target and modify the pathway-of-assembly of subunits within multimeric chromatin remodeling complexes, and to elucidate the structural, biochemical and genomic retargeting-based consequences of recurrent complex mutations.
Filed on July 14, 2017.
Tell us what you know about Cigall Kadoch's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Cigall Kadoch filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics | $200,000 - $249,999 |
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics | $150,000 - $199,999 |
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics | $0 - $4,999 |
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics, Inc. | Value cannot be readily determined |
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics | Value cannot be readily determined |
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics | Value cannot be readily determined |
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.